Luis Mejia-Lara
San Fernando No. 22, CP. 14080
Tlalpan, DIF 14080, Mexico
Tlalpan, DIF 14080, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Preserving Tradition, Preventing Cancer: A Narrative Review of the Traditional Mexican Diet as a Framework for Cancer Risk Reduction.
Journal: Plant foods for human nutrition (Dordrecht, Netherlands)
Published: March 17, 2026
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Journal: Nature communications
Published: December 12, 2025
Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 27, 2025
Correction: Perilesional edema diameter associated with brain metastases as a predictive factor of response to radiotherapy in non-small cell lung cancer.
Journal: Frontiers in oncology
Published: October 17, 2025
Cancer as trauma: multidimensional determinants of PTSD across the disease course. A narrative integrative review.
Journal: Frontiers in psychology
Published: October 06, 2025
Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256.
Journal: Cancers
Published: September 17, 2025
Letter in Response.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 11, 2024
Preclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma.
Journal: Marine drugs
Published: October 18, 2024
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Journal: Nature communications
Published: July 29, 2024
EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report.
Journal: Oncology research and treatment
Published: July 20, 2024
Last Updated: 09/26/2026